Relevant Market Insights
India’s biopharmaceutical sector is at a pivotal point in its evolution. Long celebrated as the world’s “pharmacy of the world” for generics and vaccines, the broader biopharma market is now defined by robust growth, expanding innovation, and compelling projections for the coming decade. Supported by strong domestic demand, favourable government policy, and growing global engagement, the sector’s trajectory reflects both enduring strengths and emerging opportunities.
In this blog, we explore the latest data, forward-looking projections, and the key forces driving—and shaping—the Indian biopharma market.
Market Size and Growth Trends
The Indian pharmaceutical and biopharma market has demonstrated steady expansion in recent years:
- In 2025, the Indian pharmaceutical market was valued at approximately ₹4,71,295 crore (around US$55 billion), with expectations to reach ₹10,28,280–₹11,13,970 crore (US$120–130 billion) by 2030. This implies a strong compound annual growth trajectory and reflects sustained demand across therapy areas.
- Market monitoring by industry analysts shows solid year-on-year growth. For example, the Indian pharmaceutical market grew 7.2% in May 2025, with notable value increases across key segments such as cardiac and gastrointestinal therapies.
- Recent reports also indicate robust monthly performance, such as 11.5% growth recorded in June 2025, pointing to accelerating momentum in the sector.
These figures highlight a market that is not only growing consistently but also diversifying in terms of segments and therapeutic focus.
Biopharma’s Share in the Bioeconomy
India’s broader biotechnology sector of which biopharma is a central part has shown remarkable expansion:
- The bioeconomy expanded from approximately ₹86,880 crore in 2015 to over ₹11,29,440 crore by 2024 (about US$130 billion), underlining rapid growth across biotech subsectors including biopharmaceuticals.
- Projections suggest the bioeconomy could reach around ₹26,06,400 crore (US$300 billion) by 2030, with biopharma maintaining a dominant share, driven by biologics, vaccines, biosimilars, and related services.
Within this broader picture, the biopharma segment accounts for roughly 49% of the bioeconomy’s value today, illustrating its central role in India’s biotech landscape.
Key Market Drivers
Domestic Demand and Epidemiological Trends
India’s large and aging population, rising incidence of chronic diseases such as diabetes and cardiovascular disorders, and expanding healthcare access contribute to robust domestic demand for biopharmaceutical products. Consistent demand supports sustained market expansion for both traditional medicines and newer biologic therapies.
Export Strength and Global Integration
Indian firms are integral to global healthcare supply chains. The country remains one of the largest suppliers of generic medications globally, estimated to provide about 20% of the world’s generic drugs by volume and a substantial proportion of global vaccines.
Exports are a major contributor to the sector’s growth, with facilities compliant with international regulatory standards (e.g., US FDA and WHO GMP) supporting global distribution and trade.
Innovation and Technology Adoption
Biopharmaceutical innovation including biosimilars, advanced biologics, and vaccine development is gaining traction. Strategic public-private partnerships and investments in R&D infrastructure have sparked new initiatives that could sharpen India’s competitive edge in high-value biotech products.
Future Projections and Outlook
Looking ahead through the end of the decade:
- Industry forecasts envision the Indian bioeconomy growing toward US$300 billion by 2030, buoyed by strong biopharma performance and related biotech segments.
- Biopharma’s expanding share and increasing global engagement position India to capture a growing portion of the global biotech market, particularly in areas like biosimilars, vaccines, and biologics.
- Domestic policy measures, including Production Linked Incentives (PLIs) for pharma, and sector initiatives designed to enhance manufacturing, workforce skills, and regulatory alignment are expected to foster long-term growth.
Conclusion
India’s biopharma market has moved beyond its traditional role as a generics and vaccine supplier to become a dynamic growth engine within the country’s broader biotechnology landscape. With solid market expansion, compelling medium- to long-term projections, and structural drivers such as rising domestic healthcare demand and export-oriented capacity, the sector is positioned for significant advances. Continued innovation, supportive policy frameworks, and global integration are likely to shape its trajectory over the decade ahead enabling India to play an increasingly strategic role in global biopharmaceutical innovation and supply.
No Comment! Be the first one.